MDS 2023 | Opportunities and challenges in incorporating NGS panels into clinical practice and diagnosis of MDS
Jason Cheng, The University of Chicago, Chicago, IL, comments on the advantages and disadvantages of incorporating next-generation sequencing (NGS) panels into clinical practice for the diagnosis of patients with myelodysplastic syndromes (MDS). Dr Cheng explains that NGS panels are easily implemented and can provide a large amount of information about mutations which can assist in diagnosis in some cases. However, Dr Cheng warns of over-diagnosis and over-treatment, as some MDS-associated mutations are common in older patients and may not necessarily be indicative of disease. It is therefore important not to diagnosis a patient using mutation data alone. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
